Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- PBYI reported a narrower adjusted loss in Q1 of 2024. - Q1 total revenues were $43.8 million, beating estimates. - Product revenues from Nerlynx were $40.3 million. - PBYI expects Nerlynx product sales to be $183-$190 million in 2024. - PBYI in-licensed alisertib for clinical development. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
- PBYI reported a narrower adjusted loss in Q1 of 2024.
- Q1 total revenues were $43.8 million, beating estimates.
- Product revenues from Nerlynx were $40.3 million.
- PBYI expects Nerlynx product sales to be $183-$190 million in 2024.
- PBYI in-licensed alisertib for clinical development.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.